Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Yoshishige Samukawa

Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment

Clinical Pharmacology in Drug Development
PharmacologyPharmaceutical Science
2018English

Related publications

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients With Type 2 Diabetes Mellitus

Advances in Therapy
MedicinePharmacology
2015English

Safety, Pharmacokinetics and Pharmacodynamics of Remogliflozin Etabonate, a Novel SGLT2 Inhibitor, and Metformin When Co-Administered in Subjects With Type 2 Diabetes Mellitus

BMC pharmacology & toxicology
MedicinePharmacology
2013English

The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus

Journal of Clinical Pharmacology
Pharmacology
2017English

Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Combination With Insulin in Japanese Patients With Type 1 Diabetes

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Linagliptin Added to Sulphonylurea in Uncontrolled Type 2 Diabetes Patients With Moderate-To-Severe Renal Impairment

Diabetes and Vascular Disease Research
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2013English

Luseogliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, Preserves Renal Function Irrespective of Acute Changes in the Estimated Glomerular Filtration Rate in Japanese Patients With Type 2 Diabetes

Hypertension Research
Internal MedicineCardiovascular MedicinePhysiologyCardiology
2020English

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects

Drug Metabolism and Pharmacokinetics
PharmacologyPharmaceutical Science
2013English

Ertugliflozin: A New SGLT2 Inhibitor for Type 2 Diabetes

Prescriber
Pharmacology
2019English

Effective SGLT2 Inhibitor for Patient With Type 2 Diabetes Mellitus (T2DM) and Depression

2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy